Jan Gerstoft

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA

Nathan Clumeck, F. D. Goebel, Willy Rozenbaum et al. · AIDS · 2001 · 145 citations

Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?

Ole Kirk, Jens Lundgren, Court Pedersen et al. · AIDS · 1999 · 99 citations

Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues

Kristien Van Vaerenbergh, Kristel Van Laethem, Jan Albert et al. · Antimicrobial Agents and Chemotherapy · 2000 · 95 citations · Full text

Primary Immunodeficiency, Resistance Patterns, Human Retrovirus +14

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax et al. · The Lancet HIV · 2019 · 92 citations

Treatment And Prevention, Antiretroviral-naive Adults, Clinical Trials +6

Development of resistance to zidovudine (ZDV) and didanosine (ddl) in HIV from patients in ZDV, ddl and alternating ZDV/ddl therapy

Claus Henrik Nielsen, L Bruun, Court Pedersen et al. · AIDS · 1996 · 23 citations